The Insider: Meet the CEOs Webcast Replay
We were joined by the CEOs of exciting ASX-listed businesses, who gave valuable insight to their industries and companies future prospects.
- (ASX: TZL) TZ Limited – Mario Vecchio, CEO
- (ASX: WNX) Wellnex Life – George Karafotias, CEO
- (ASX: MVF) Monash IVF Group – Michael Knaap
Recorded on 27 October 2021 at 12pm (AEDT).
FEATURED SPEAKERS
Mario Vecchio
Chief Executive Officer - TZ Limited (ASX: TZL)
TZ Limited is a tech innovator that has been at the forefront of Internet of Things research and development since 2004, and is uniquely positioned as a category leader and disruptor. The company solves real-world problems, by engineering software solutions centred around access and control of physical spaces. TZ has demonstrated success with an expanding US pipeline and an A-list client base, including companies such as Apple, Microsoft, Google, Amazon and Westpac. The company is targeting significant recurring revenue growth with a shift to multi-term software service agreements and enabling third-party access through their SaaS platform.
George Karafotias
Chief Executive Officer - Wellnex Life (ASX: WNX)
Wellnex Life is a brand developer and distributor of health and wellness products in the growing $5.6 billion Australian health and wellness market. Partnering with some of Australia’s largest retailers, including Chemist Warehouse, Woolworths and Coles, the company is poised to be a disruptor in the industry. Wellnex has grown its revenue from $6.7 million to $18.3 million in three years, and is forecast to exceed $21 million in revenue in FY22. A large portfolio, first-to-market strategy and an established retail distribution network provide an attractive business model for growth and profitability.
Michael Knaap
Chief Executive Officer - Monash IVF Group (ASX: MVF)
Monash IVF Group is the pioneer of IVF and a global leader in assisted reproductive services, genetic testing and ultrasound services. The company was the first to achieve successful IVF and has since been a driving force in the development of assisted reproductive technologies and tertiary level prenatal diagnostics. Monash IVF Group currently has a market share of 21% and operates more than 40 fertility and ultrasound clinics across Australia. Showing a 61.5% increase in net profits and 26.3% revenue growth in FY21, the company is poised to grow considerably with the increasing demand for fertility services.
